| Project/Area Number |
23K27432
|
|---|
| Project/Area Number (Other) |
23H02741 (2023)
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Multi-year Fund (2024)
Single-year Grants (2023) |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Rashad Sherif 東北大学, 医工学研究科, 准教授 (00824088)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
遠藤 俊毅 東北医科薬科大学, 医学部, 教授 (00535370)
七谷 圭 東北大学, 未来型医療創成センター, 助教 (00547333)
新妻 邦泰 東北大学, 医工学研究科, 教授 (10643330)
金森 政之 東北大学, 医学系研究科, 准教授 (60420022)
|
|---|
| Project Period (FY) |
2023-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2024)
|
| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2025: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2024: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2023: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Keywords | tRNA / Glioma / Codon bias / mRNA translation / Ferroptosis |
|---|
| Outline of Research at the Start |
tRNA modifications were shown to impact cancer pathophysiology. Here, using high throughput mass spectrometry coupled to sequencing analysis, we will identify target tRNA modifications that can be further explored for glioma therapy.
|
| Outline of Annual Research Achievements |
During the past year, I was able to finish 2 manuscripts related to tRNA modifications and their potential role. The manuscripts were published as preprints and currently are under review (Al-Mesitef et al, 2024; Rashad et al, 2024). I also presented the preliminary results of my work in the RNA society meeting 2023 in Singapore and The American Society for Cell Biology 2023 in Boston. I was also able to improve the mass spectrometry method and analyze patient derived glioma samples that led to major discovery in terms of tRNA modifications and glioma that is currently being explored.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
Analysis of patient drived glioma samples revealed many tRNA modifications of interest that will be systematically targeted in the next stage. The progress in the analysis of ALKBH1 in glioma is going smoothly and a manuscript is expected to be prepared this year. Structural studies are underway.
|
| Strategy for Future Research Activity |
The orignal plan will continue with expansion to a number of tRNA modifications based on the analysis conducted.
|
